UCB announces approval of Bimzelx
31st August 2023 Uncategorised 0The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis More: UCB announces approval of Bimzelx Source: News
read moreThe therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis More: UCB announces approval of Bimzelx Source: News
read moreThe candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis More: BenevolentAI doses participants in BEN-8744 study Source: News
read moreWith $25K donation to Pence PAC, Lilly CEO Ricks defies some of company’s stated positions fkansteiner Wed, 08/30/2023 – 11:04 More: With K donation to Pence PAC, Lilly CEO Ricks defies some of company's stated positions Source: fierce
read moreAmid shortage, FDA clears several generics of Takeda’s popular ADHD drug Vyvanse zbecker Wed, 08/30/2023 – 11:04 More: Amid shortage, FDA clears several generics of Takeda's popular ADHD drug Vyvanse Source: fierce
read moreFDA turns down Outlook’s ophthalmic version of Roche’s Avastin over manufacturing, data shortfalls aliu Wed, 08/30/2023 – 10:32 More: FDA turns down Outlook's ophthalmic version of Roche's Avastin over manufacturing, data shortfalls Source: fierce
read moreJohnson & Johnson’s spinoff of Kenvue provides $13.2B in potential M&A firepower kdunleavy Wed, 08/30/2023 – 10:10 More: Johnson & Johnson's spinoff of Kenvue provides .2B in potential M&A firepower Source: fierce
read more© 1994 - 2024 B.M. Pharmaceuticals